netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 Formulary Chapter 5: Infections - Full Chapter
05.04.01  Expand sub section  Antimalarials
05.04.01  Expand sub section  Treatment of malaria
Artesunate (Malacef 60)
View adult BNF View SPC online View SMC online

Injection: 60mg

05.04.01  Expand sub section  Falciparum malaria (treatment)
05.04.01  Expand sub section  Benign malarias (treatment)
05.04.01  Expand sub section  Prophylaxis against malaria to top
05.04.01  Expand sub section  Specific recommendations
05.04.01  Expand sub section  Artemether with lumefabtrine
05.04.01  Expand sub section  Chloroquine
05.04.01  Expand sub section  Mefloquine
05.04.01  Expand sub section  Primaquine to top
05.04.01  Expand sub section  Proguanil
05.04.01  Expand sub section  Pyrimethamine
05.04.01  Expand sub section  Quinine
05.04.01  Expand sub section  Tetracyclines
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Drugs for hospital use only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician. These drugs should only be prescribed under the direct supervision of that clinician and are not suitable for shared care arrangements. The drug should be supplied via the hospital for the duration of treatment.   


These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. An information leaflet may be provided in order to facilitate ongoing prescribing in primary care.   


These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.